Tirzepatide

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. It is designed to improve glycemic control in adults with type 2 diabetes mellitus. Tirzepatide works by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying, which helps to lower blood sugar levels. In addition to its effects on blood glucose, tirzepatide has also been shown to promote weight loss, making it a promising treatment option for individuals with obesity and type 2 diabetes. Clinical trials have demonstrated significant improvements in glycemic control and weight reduction with tirzepatide compared to other treatments, positioning it as a potential game-changer in the management of type 2 diabetes.